Boosting protection: can an extra vaccine dose shield cancer survivors from pneumonia?
NCT ID NCT06049134
Summary
This study is testing whether giving two doses of a pneumonia vaccine works better than one dose for people who have survived B-cell lymphoma. The goal is to see which approach gives stronger, longer-lasting protection against serious lung infections. The study involves 30 adults whose lymphoma has been in remission for at least a year after receiving specific anti-CD20 treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.